Literature DB >> 23258808

Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD).

Ursula Verdalles1, Soledad García de Vinuesa, Marian Goicoechea, Borja Quiroga, Javier Reque, Nayara Panizo, David Arroyo, José Luño.   

Abstract

BACKGROUND: Expansion of extracellular volume (ECV) is a frequent cause of resistant hypertension (RHT) in patients with chronic kidney disease (CKD). The aim of this exploratory study was that of applying bioimpedance spectroscopy (BIS) for the identification of CKD patients with RHT and expansion of ECV, while trying to control blood pressure (BP) using an intensification of diuretic treatment.
METHODS: We included 50 patients with RHT and CKD who underwent BIS. In order to control BP, diuretic treatment was intensified in those patients with expansion of the ECV. In all other cases, another antihypertensive drug was added.
RESULTS: The mean age was 68.2 ± 10.4 years, 68% were male and 58% were diabetic. The mean estimated glomerular filtration rate (eGFR) was 50.7 ± 22.4 mL/min/1.72 m(2). Baseline systolic BP was 167.2 ± 8.6 mmHg and diastolic BP was 84.8 ± 9.5 mmHg. The mean number of antihypertensive drugs received was 3.8 ± 0.9. Expansion of ECV was recorded in 30 (60%) patients and was more frequent in diabetics and in patients with more albuminuria. At 6 months of follow-up, a decline of 21.4 ± 7.1 mmHg was observed in systolic BP in the patients with expansion of ECV, compared with a decrease of 9.4 ± 3.4 mmHg in the normal ECV group (P < 0.01). We did not find differences in the decrease in diastolic BP between the groups. Nine patients (30%) with ECV expansion who increased diuretic therapy reached the target blood pressure (BP) of <140/90 mmHg, when compared with only two patients (10%) who had normal ECV and in whom other antihypertensive drug was added. A total decrease in body water of 1.9 ± 1.1 L was observed in patients with ECV expansion who intensified diuretic treatment at the expense of a decline in ECV of 1.1 ± 1 L. eGFR remained stable in both groups (47.1 ± 21.1 versus 54.1 ± 25.2 mL/min/1.73 m(2); P = 0.37).
CONCLUSIONS: An increase in ECV as measured by BIS frequently occurs in RHT in patients with CKD. Diabetic and severe proteinuric patients are more exposed to expansion of ECV. BIS is a potentially useful method for identifying and treating patients with RHT and expansion of ECV. The hypothesis generated by this exploratory study needs to be tested in a randomized clinical trial.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23258808     DOI: 10.1093/ndt/gfs420

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease: Managing Volume Overload.

Authors:  Carmine Zoccali; Francesca Mallamaci
Journal:  Clin J Am Soc Nephrol       Date:  2018-08-15       Impact factor: 8.237

Review 2.  Recognition and Management of Resistant Hypertension.

Authors:  Branko Braam; Sandra J Taler; Mahboob Rahman; Jennifer A Fillaus; Barbara A Greco; John P Forman; Efrain Reisin; Debbie L Cohen; Mohammad G Saklayen; S Susan Hedayati
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-28       Impact factor: 8.237

Review 3.  Current issues in the management and monitoring of hypertension in chronic kidney disease.

Authors:  Pranav S Garimella; Katrin Uhlig
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-11       Impact factor: 2.894

Review 4.  Loop Diuretics in the Treatment of Hypertension.

Authors:  Line Malha; Samuel J Mann
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

5.  Any grade of relative overhydration is associated with long-term mortality in patients with Stages 4 and 5 non-dialysis chronic kidney disease.

Authors:  Almudena Vega; Soraya Abad; Nicolás Macías; Inés Aragoncillo; Ana García-Prieto; Tania Linares; Esther Torres; Andrés Hernández; José Luño
Journal:  Clin Kidney J       Date:  2018-03-28

6.  Abnormal urinary excretion of NKCC2 and AQP2 in response to hypertonic saline in chronic kidney disease: an intervention study in patients with chronic kidney disease and healthy controls.

Authors:  Janni M Jensen; Frank H Mose; Anna-Ewa O Kulik; Jesper N Bech; Robert A Fenton; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2014-06-26       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.